到 2027 年亚太地区给药系统市场 - 按给药途径（经粘膜、口服、注射、局部、植入和眼部）进行区域分析和预测；分销渠道（医院药房、零售药房、网上药房）；和申请（家庭护理机构、医院和诊所等）和国家/地区
No. of Pages: 223 | Report Code: TIPRE00006839 | Category: Life Sciences
No. of Pages: 223 | Report Code: TIPRE00006839 | Category: Life Sciences
亚太地区给药系统市场预计将从 2018 年的 212,012.7 美元增至 2027 年的 441,337.0 百万美元。预计从 2019 年开始，该市场将以 8.6% 的复合年增长率增长-2027。
推动市场增长的关键因素是慢性病发病率的上升以及对非侵入性给药设备的需求不断增长。然而，制约市场增长的因素是产品开发的研发成本较高。然而，开发药物输送设备的高成本可能会对未来几年的市场增长产生负面影响。
在亚太地区，正在研究各种给药途径以治疗这些慢性疾病。据亚太疾病负担估计，印度心血管疾病死亡率约为每10万人272人，相对高于亚太地区平均水平（每10万人235人）。澳大利亚、中国、韩国和澳大利亚等亚洲国家也出现了类似的糖尿病患病率上升趋势。例如，根据国际糖尿病联合会 2017 年发布的 IDF 糖尿病地图集，东南亚几乎占亚太地区糖尿病人口的五分之一 (19%)。根据世界卫生组织（WHO）公布的数据，2014年中国约有2.3亿人患有心血管疾病。此外，考虑到中国人口老龄化和经济增长，到 2030 年，这一数字预计将增加 50%。此外，到2030年，心血管疾病将给中国政府造成10,440亿美元的损失。老年人口和相关慢性病的增加预计将推动医疗器械的销售，从而导致亚太地区市场在预测几年内的增长。亚太地区癌症患病率日益上升的问题日益严重。 该地区的报告显示，日本、台湾、新加坡、韩国、马来西亚、泰国、中国、菲律宾、斯里兰卡、越南、印度尼西亚、蒙古、印度、老挝和柬埔寨是拥有最多 15 个国家/地区的国家/地区癌症患病率。由于慢性病病例的增加，药物输送系统市场可能会推动预测期内的增长。
;
预计在预测期内，中国将引领亚太地区药物输送系统的采用。药物输送技术方面的研究活动不断增加，疾病患病率显着增加，推动科学和创新的合作和伙伴关系数量不断增加。预计中国还将在未来几年内为本地和国际企业提供在国内制造和销售给药装置的利润丰厚的机会。
< span>
亚太地区给药系统市场细分
作者
给药途径
提及的公司
< /p>
Strategic insights for Asia Pacific Drug Delivery System involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2018 | US$ 212,012.7 Million |
| Market Size by 2027 | US$ 441,337.0 Million |
| Global CAGR (2019 - 2027) | 8.6% |
| Historical Data | 2016-2017 |
| Forecast period | 2019-2027 |
| Segments Covered |
By 给药途径
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia Pacific Drug Delivery System refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The List of Companies
The Asia Pacific Drug Delivery System Market is valued at US$ 212,012.7 Million in 2018, it is projected to reach US$ 441,337.0 Million by 2027.
As per our report Asia Pacific Drug Delivery System Market, the market size is valued at US$ 212,012.7 Million in 2018, projecting it to reach US$ 441,337.0 Million by 2027. This translates to a CAGR of approximately 8.6% during the forecast period.
The Asia Pacific Drug Delivery System Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Drug Delivery System Market report:
The Asia Pacific Drug Delivery System Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Drug Delivery System Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Drug Delivery System Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Drug Delivery System Market
